Nektar Therapeutics (NKTR NASDAQ) stock market data APIs
$37.594
0.61(1.6%)
as of February 4, 2026
Try our APIs with
free plan!
Nektar Therapeutics Financial Data Overview
Price chart is built with
Anychart
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution processes of inflammation and has applications in a number of therapeutic indications, including acute and chronic inflammation; Tumor necrosis factor (TNF) receptor type II (TNFR2) agonist asset is a bivalent antibody molecule used to selectively stimulate TNFR2 receptor activity, without modulation of the TNFR1 signaling; and NKTR-255, an IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.
Prev. Close
37.594
Open
38.202
High
39.2125
Low
36.4871
52 wk Range
6.45-66.92
Market Cap
766 M
Shares Outstanding
20 342 K
Revenue
62 600 K
EPS
-1.87
Beta
1.335
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Nektar Therapeutics (top by weight)
Ticker
100-day Price Change
Weight
POAGX.US
PRIMECAP ODYSSEY AGGRESSIVE GROWTH FUND PRIMECAP ODYSSEY AGGRESSIVE GROWTH FUND
8.78
(20.57%)
5.33
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Nektar Therapeutics data using free add-ons & libraries
Get Nektar Therapeutics Fundamental Data
Nektar Therapeutics Fundamental data includes:
- Net Revenue: 62 600 K
- EBITDA: -135 195 008
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-06
- EPS/Forecast: -0.1928
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Nektar Therapeutics News
New
Stocks making the biggest moves premarket: L3Harris, JPMorgan, Delta, Intel, AMD and more
Check out the companies making headlines before the bell: JPMorgan Chase — The banking giant rose around 1% on fourth-quarter figures that beat analyst expectations. JPMorgan earned $5.23 per share,...
Zacks Industry Outlook Highlights Soleno Therapeutics, Nektar Therapeutics, Rigel Pharmaceuticals, Ironwood Pharmaceuticals and Marker Therapeutics
For Immediate Release Chicago, IL – January 8, 2026 – Today, Zacks Equity Research discusses Soleno Therapeutics SLNO, Nektar Therapeutics NKTR, Rigel Pharmaceuticals RIGL, Ironwood Pharmaceutica...
5 Small Drug Stocks to Buy as Industry Recovery Picks Up
After a sluggish first half, the drug and biotech sector has staged a recovery over the past two to three months. This rebound was supported by major drugmakers signing drug pricing agreements with th...
How The Narrative Around Nektar Therapeutics (NKTR) Is Shifting With Rezpeg Data And Litigation Risks
Nektar Therapeutics just saw its fair value model refreshed, with the headline number holding steady at US$114.43 per share even as the long term revenue growth assumption for Rezpeg edged to a 10.83%...
Get Nektar Therapeutics fresh news feed via Financial News API
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
